Ascher laboratory: Structural biology and bioinformatics
Head of LaboratoryDr David Ascher
Location: Bio21 Institute, 30 Flemington Rd
On-going technological advancements have led to dramatic increases in the amounts of biological data being generated. Along with the evolution of high performance computing and computational tools, this has provided us with a wealth of information, analytical power and the opportunity to investigate fundamental health and biotechnological problems of a different magnitude and kind, complementary to and able to guide conventional approaches. Our group is interested in developing and experimentally validating novel computational methods to exploit this data, enhancing the impact of genome sequencing, structural genomics, and functional genomics on biology and medicine.
One of our main areas of interest is in the development of predictive and analytical tools and databases to investigate and understand the relationship between protein sequence, structure and function and phenotype, allowing us to gain unique insights into:
- The molecular basis of genetic diseases, including cancer;
- Understanding the molecular mechanisms behind drug resistance, to guide personalized patient treatment and the development of resistance resistant drugs;
- Evolutionary insights derived from the analysis of protein structure and function;
- Small molecule activity and toxicity as an aid to the design of novel drugs.
Keywords: Machine learning, databases, mutations, genetic disease, drug resistance, cancer, molecular mechanism, homology modelling, protein structure and function, small molecules, drug development.
We have developed and host a wide range of widely used and freely-available tools, including:
- Arpeggio: Calculation and visualisation of all molecular interactions.
- mCSM-Stability: Predicting effects of mutations on protein stability.
- DUET: An integrated method for predicting effects of mutations on protein stability.
- mCSM-PPI (http://bleoberis.bioc.cam.ac.uk/m: Predicting effects of mutations on the affinity of protein-protein interactions.
- mCSM-AB: Predicting effects of mutations on antibody-antigen binding affinity.
- mCSM-NA: Predicting effects of mutations on the affinity of protein-nucleic acid interactions.
- mCSM-lig: Predicting effects of protein mutations on affinity for small molecules.
- CSM-lig: Predicting the protein binding affinity of small molecules.
- KAMP: Identification of protein kinase activating mutations.
- pkCSM: Predicting small molecule pharmacokinetic and toxicity properties.
- Platinum DB: Structural database of experimentally measured effects of missense mutations on protein-ligand complexes.
- TROMBONE DB: Optimisation of Botulinum and Tetnus neurotoxins for medicinal purposes.
- Symphony DB: Classification of VHL missense mutations according to risk of clear cell Renal carcinoma.
Dr Douglas Pires (Fiocruz-Minas)
Liviu Copoiu, PhD Student (Cambridge, UK), co-supervised by Professor Sir Tom Blundell
Efrem Lousada, PhD Student (UFMG, Brazil), co-supervised with Douglas Pires
Carlos Henrique Miranda Rodrigues, Masters Student (UFMG / CPqRR, Brazil), CNPq , co-supervised with Douglas Pires
Amanda Tábita da Silva Albanaz, Undergraduate Research Student (PROBIC - Fapemig, Brazil), CNPq, co-supervised with Douglas Pires
Professor Sir Tom Blundell, University of Cambridge
Professor Eamonn Maher, University of Cambridge
Professor Taane Clark, London School of Hygiene & Tropical Medicine
Dr Nick Furnham, London School of Hygiene & Tropical Medicine
Professor Sergio Pena, UFMG
Dr Andrea Zatkova, Slovak Academy of Sciences
Professor Lakshminarayan Ranganath, University of Liverpool
Dr Lisa Kaminskas, University of Queensland
Dr Katerina Artavanis-Tsakonas, University of Cambridge
Professor Véronique Dartois, Public Health Research Institute Center
Professor Taís Nóbrega de Sousa, Fiocruz-Minas
Newton Fund/MRC: "Understanding Antimicrobial Resistance Mutations in Tuberculosis: Towards Personalised Treatment to Combat Multi‐drug Resistance".
Jack Brockhoff Foundation Grant: “Understanding the Molecular Mechanisms of Complex Mutations”.
This research project is available to PhD students to join as part of their thesis.
Please contact the Research Group Leader to discuss your options.
Click here for the results of a PubMed search of David's publications.
Click here for the results of a Google Scholar analysis of David's publications.
- Pires DEV, Chen J, Blundell TL, Ascher DB. In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity. Scientific Reports 2016; 6: 19848.
- Pires DEV, Blundell TL, Ascher DB. mCSM-lig: quantifying the effects of mutations on protein-ligand affinity in genetic disease and the emergence of drug resistance. Scientific Reports 2016; 6: 29575.
- Pires DEV, Ascher DB. mCSM-AB: a web server for predicting antibody-antigen affinity changes upon mutation with graph-based signatures. Nucleic Acids Research 2016; 44: W469-473.
- Pires DEV, Ascher DB. CSM-lig: a web server for assessing and comparing protein-small molecule affinities. Nucleic Acids Research 2016; 44: W557-561.
- Pires DEV, Blundell TL, Ascher DB. pkCSM: predicting small-molecule pharmacokinetic properties using graph-based signatures. Journal of Medicinal Chemistry 2015; 58(9): 4066-4072.
- Phelan J, Coll F, McNerney R, Ascher DB, Pires DE, Furnham N, Coeck N, Hill-Cawthorne GA, Nair MB, Mallard K, Ramsay A, Campino S, Hibberd ML, Pain A, Rigouts L, Clark TG. Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance. BMC Medicine 2016; 14: 31.
- Jafri M, Wake NC, Ascher DB, Pires DEV, Gentle D, Morris MR, Rattenberry E, Simpson MA, Trembath RC, Weber A, Woodward ER, Donaldson A, Blundell TL, Latif F, Maher ER. Germline Mutations in the CDKN2B tumor suppressor gene predispose to renal cell carcinoma. Cancer Discovery 2015; 5(7): 723-729.
- Jubb H, Blundell TL, Ascher DB. Flexibility and small pockets at protein-protein interfaces: new insights into druggability. Progress in Biophysics and Molecular Biology 2015; 119(1): 2-9.
- Pires DEV, Ascher DB, Blundell TL. mCSM: predicting the effect of mutations in proteins using graph-based signatures. Bioinformatics 2014; 30(3): 335-342.
- Ascher DB, Wielens J, Nero TL, Morton CJ, Parker MW. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Scientific Reports 2014;. 4: 4765.
- Understanding the molecular consequences of mutations
- Personalising treatments for genetic diseases
- Tackling drug resistance
- Designing better drugs
- Protein engineering
- Analysing protein structures
Faculty Research Themes
School Research Themes
For further information about this research, please contact Dr David Ascher